https://www.biospace.com/china China en-US Fri, 03 Jul 2026 11:16:04 GMT https://www.biospace.com/press-releases/brii-bio-announces-topline-end-of-treatment-data-from-phase-2b-enrich-and-enhance-studies-for-the-treatment-of-chronic-hepatitis-b Fri, 03 Jul 2026 11:16:04 GMT https://www.biospace.com/press-releases/brii-bio-announces-topline-end-of-treatment-data-from-phase-2b-enrich-and-enhance-studies-for-the-treatment-of-chronic-hepatitis-b https://www.biospace.com/press-releases/multitude-therapeutics-announces-encouraging-interim-phase-i-results-from-ongoing-first-in-human-study-evaluating-its-cdh17-directed-antibody-drug-conjugate-amt-676-in-patients-with-advanced-crc-at-the-2026-esmo-gi-cancer-congress • AMT-676 is a potential first-in-class CDH17-directed ADC with a proprietary exatecan-based linker-payload design • AMT-676 demonstrated a favorable safety profile, similar to other TOP1-inhibitor based ADCs with reduced hematological toxicities • Promising antitumor activity was observed in heavily pretreated CRC patients Thu, 02 Jul 2026 21:42:41 GMT https://www.biospace.com/press-releases/multitude-therapeutics-announces-encouraging-interim-phase-i-results-from-ongoing-first-in-human-study-evaluating-its-cdh17-directed-antibody-drug-conjugate-amt-676-in-patients-with-advanced-crc-at-the-2026-esmo-gi-cancer-congress https://www.biospace.com/press-releases/burning-rock-announces-founders-purchase-of-its-adss Thu, 02 Jul 2026 12:18:48 GMT https://www.biospace.com/press-releases/burning-rock-announces-founders-purchase-of-its-adss https://www.biospace.com/press-releases/hutchmed-announces-nmpa-approval-for-orpathys-for-the-treatment-of-gastric-cancer-patients-with-met-amplification Thu, 02 Jul 2026 12:05:35 GMT https://www.biospace.com/press-releases/hutchmed-announces-nmpa-approval-for-orpathys-for-the-treatment-of-gastric-cancer-patients-with-met-amplification https://www.biospace.com/press-releases/abbisko-therapeutics-and-astrazeneca-enter-a-strategic-collaboration-to-conduct-the-clinical-trial-of-lumipodlin-absk043-a-first-in-class-oral-pd-l1-inhibitor-in-combination-with-tagrisso-for-nsclc Thu, 02 Jul 2026 03:56:43 GMT https://www.biospace.com/press-releases/abbisko-therapeutics-and-astrazeneca-enter-a-strategic-collaboration-to-conduct-the-clinical-trial-of-lumipodlin-absk043-a-first-in-class-oral-pd-l1-inhibitor-in-combination-with-tagrisso-for-nsclc https://www.biospace.com/press-releases/junshi-biosciences-enters-licensing-collaboration-with-fosun-wanbang-on-roconkibart-il-17a Thu, 02 Jul 2026 03:52:53 GMT https://www.biospace.com/press-releases/junshi-biosciences-enters-licensing-collaboration-with-fosun-wanbang-on-roconkibart-il-17a https://www.biospace.com/press-releases/vyome-granted-chinese-patent-strengthening-immuno-inflammation-portfolio Wed, 01 Jul 2026 13:30:07 GMT https://www.biospace.com/press-releases/vyome-granted-chinese-patent-strengthening-immuno-inflammation-portfolio https://www.biospace.com/press-releases/hutchmed-to-announce-2026-half-year-financial-results Tue, 30 Jun 2026 11:37:55 GMT https://www.biospace.com/press-releases/hutchmed-to-announce-2026-half-year-financial-results https://www.biospace.com/press-releases/wuxi-biologics-receives-brazil-anvisa-gmp-certification-to-enable-global-commercial-manufacturing-of-innovative-cancer-immunotherapy Tue, 30 Jun 2026 11:35:49 GMT https://www.biospace.com/press-releases/wuxi-biologics-receives-brazil-anvisa-gmp-certification-to-enable-global-commercial-manufacturing-of-innovative-cancer-immunotherapy https://www.biospace.com/press-releases/hengruis-heng-yi-approved-in-china-as-an-innovative-cyclosporine-ophthalmic-solution-for-the-treatment-of-dry-eye-disease Tue, 30 Jun 2026 06:51:43 GMT https://www.biospace.com/press-releases/hengruis-heng-yi-approved-in-china-as-an-innovative-cyclosporine-ophthalmic-solution-for-the-treatment-of-dry-eye-disease https://www.biospace.com/press-releases/innovent-biologics-and-lilly-enter-into-commercialization-agreement-for-verzenios-abemaciclib-in-mainland-china Tue, 30 Jun 2026 06:39:20 GMT https://www.biospace.com/press-releases/innovent-biologics-and-lilly-enter-into-commercialization-agreement-for-verzenios-abemaciclib-in-mainland-china https://www.biospace.com/press-releases/excalipoint-therapeutics-announces-clinical-trial-collaboration-with-roche-to-evaluate-exp011-in-dll3-expressing-solid-tumors Tue, 30 Jun 2026 01:02:35 GMT https://www.biospace.com/press-releases/excalipoint-therapeutics-announces-clinical-trial-collaboration-with-roche-to-evaluate-exp011-in-dll3-expressing-solid-tumors https://www.biospace.com/press-releases/alebund-pharmaceuticals-09637-hk-debuts-on-the-hkex-main-board Mon, 29 Jun 2026 13:46:23 GMT https://www.biospace.com/press-releases/alebund-pharmaceuticals-09637-hk-debuts-on-the-hkex-main-board https://www.biospace.com/press-releases/harbour-biomed-appoints-dr-lloyd-klickstein-as-scientific-advisor-for-immunology Mon, 29 Jun 2026 11:35:54 GMT https://www.biospace.com/press-releases/harbour-biomed-appoints-dr-lloyd-klickstein-as-scientific-advisor-for-immunology https://www.biospace.com/press-releases/universe-pharmaceuticals-inc-announces-strategic-acquisition-to-expand-pharmaceutical-patent-portfolio Mon, 29 Jun 2026 01:52:23 GMT https://www.biospace.com/press-releases/universe-pharmaceuticals-inc-announces-strategic-acquisition-to-expand-pharmaceutical-patent-portfolio https://www.biospace.com/press-releases/leads-biolabs-announces-partner-oblenio-bios-62-million-oversubscribed-series-b-financing-to-advance-tri-specific-t-cell-engager-lbl-051-for-autoimmune-diseases-into-clinical-development Thu, 25 Jun 2026 12:13:58 GMT https://www.biospace.com/press-releases/leads-biolabs-announces-partner-oblenio-bios-62-million-oversubscribed-series-b-financing-to-advance-tri-specific-t-cell-engager-lbl-051-for-autoimmune-diseases-into-clinical-development https://www.biospace.com/press-releases/cstone-pharmaceuticals-enters-into-exclusive-commercialization-agreement-with-arrotex-for-sugemalimab-across-australia-and-new-zealand Thu, 25 Jun 2026 12:11:43 GMT https://www.biospace.com/press-releases/cstone-pharmaceuticals-enters-into-exclusive-commercialization-agreement-with-arrotex-for-sugemalimab-across-australia-and-new-zealand https://www.biospace.com/press-releases/c-ray-therapeutics-receives-radiopharmaceutical-manufacturing-authorization-under-chinas-mah-framework Thu, 25 Jun 2026 05:01:09 GMT https://www.biospace.com/press-releases/c-ray-therapeutics-receives-radiopharmaceutical-manufacturing-authorization-under-chinas-mah-framework https://www.biospace.com/press-releases/innovents-partner-ollin-biosciences-announces-oversubscribed-330-million-series-b-financing-to-advance-global-phase-3-development-of-ibi324-oln324-in-dme-and-wet-amd-studies-commencing-in-second-half-of-2026 Thu, 25 Jun 2026 05:00:19 GMT https://www.biospace.com/press-releases/innovents-partner-ollin-biosciences-announces-oversubscribed-330-million-series-b-financing-to-advance-global-phase-3-development-of-ibi324-oln324-in-dme-and-wet-amd-studies-commencing-in-second-half-of-2026 https://www.biospace.com/press-releases/hkeybio-debuts-hkey-exe-1-0-to-address-preclinical-bottlenecks-in-eoe-and-ege-drug-development Thu, 25 Jun 2026 01:44:22 GMT https://www.biospace.com/press-releases/hkeybio-debuts-hkey-exe-1-0-to-address-preclinical-bottlenecks-in-eoe-and-ege-drug-development